Treating irritable bowel syndrome: Overview, perspective and future therapies

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

This article summarizes the ongoing challenges in irritable bowel syndrome and the exciting opportunities for development of novel therapies for this common, enigmatic condition. The challenges include insufficient understanding of mechanisms, lack of specificity of symptoms, differentiation from other conditions, and lack of availability of noninvasive tests to identify dysfunctions. However, significant opportunities are reflected by the advances in clinical trial design and, particularly, clinically relevant end points for such trials, and the increasing understanding of basic neuroenteric science. The latter has delivered two new medications to the practice (alosetron and tegaserod), and other candidate therapies (other serotonergic, tachykininergic, opioid, cannabinoid modulators) are being carefully appraised as potential drugs for the future.

Original languageEnglish (US)
Pages (from-to)1237-1248
Number of pages12
JournalBritish Journal of Pharmacology
Volume141
Issue number8
DOIs
StatePublished - Apr 2004

Fingerprint

Irritable Bowel Syndrome
Cannabinoids
Opioid Analgesics
Clinical Trials
Therapeutics
Pharmaceutical Preparations
tegaserod
alosetron

Keywords

  • Challenges
  • Colonic diseases
  • Functional
  • Opportunities
  • Treatment

ASJC Scopus subject areas

  • Pharmacology

Cite this

Treating irritable bowel syndrome : Overview, perspective and future therapies. / Camilleri, Michael.

In: British Journal of Pharmacology, Vol. 141, No. 8, 04.2004, p. 1237-1248.

Research output: Contribution to journalArticle

@article{570fce56ee90436e81ff1e5bd028e34e,
title = "Treating irritable bowel syndrome: Overview, perspective and future therapies",
abstract = "This article summarizes the ongoing challenges in irritable bowel syndrome and the exciting opportunities for development of novel therapies for this common, enigmatic condition. The challenges include insufficient understanding of mechanisms, lack of specificity of symptoms, differentiation from other conditions, and lack of availability of noninvasive tests to identify dysfunctions. However, significant opportunities are reflected by the advances in clinical trial design and, particularly, clinically relevant end points for such trials, and the increasing understanding of basic neuroenteric science. The latter has delivered two new medications to the practice (alosetron and tegaserod), and other candidate therapies (other serotonergic, tachykininergic, opioid, cannabinoid modulators) are being carefully appraised as potential drugs for the future.",
keywords = "Challenges, Colonic diseases, Functional, Opportunities, Treatment",
author = "Michael Camilleri",
year = "2004",
month = "4",
doi = "10.1038/sj.bjp.0705741",
language = "English (US)",
volume = "141",
pages = "1237--1248",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Treating irritable bowel syndrome

T2 - Overview, perspective and future therapies

AU - Camilleri, Michael

PY - 2004/4

Y1 - 2004/4

N2 - This article summarizes the ongoing challenges in irritable bowel syndrome and the exciting opportunities for development of novel therapies for this common, enigmatic condition. The challenges include insufficient understanding of mechanisms, lack of specificity of symptoms, differentiation from other conditions, and lack of availability of noninvasive tests to identify dysfunctions. However, significant opportunities are reflected by the advances in clinical trial design and, particularly, clinically relevant end points for such trials, and the increasing understanding of basic neuroenteric science. The latter has delivered two new medications to the practice (alosetron and tegaserod), and other candidate therapies (other serotonergic, tachykininergic, opioid, cannabinoid modulators) are being carefully appraised as potential drugs for the future.

AB - This article summarizes the ongoing challenges in irritable bowel syndrome and the exciting opportunities for development of novel therapies for this common, enigmatic condition. The challenges include insufficient understanding of mechanisms, lack of specificity of symptoms, differentiation from other conditions, and lack of availability of noninvasive tests to identify dysfunctions. However, significant opportunities are reflected by the advances in clinical trial design and, particularly, clinically relevant end points for such trials, and the increasing understanding of basic neuroenteric science. The latter has delivered two new medications to the practice (alosetron and tegaserod), and other candidate therapies (other serotonergic, tachykininergic, opioid, cannabinoid modulators) are being carefully appraised as potential drugs for the future.

KW - Challenges

KW - Colonic diseases

KW - Functional

KW - Opportunities

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=2442581507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442581507&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0705741

DO - 10.1038/sj.bjp.0705741

M3 - Article

C2 - 15037521

AN - SCOPUS:2442581507

VL - 141

SP - 1237

EP - 1248

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 8

ER -